Toronto, Ontario / ACCESSWIRE / June 12, 2014 / Theralase Technologies Inc. ("Theralase") (TSXV: TLT) (TLTFF: OTC Link(R)) announced that effective June 3, 2014, its common shares, which trade in the United States Over The Counter (OTC) market under the trading symbol TLTFF, have been upgraded on a venue change from the Grey Market to the OTC Link Market.
OTC Markets facilitates electronic trading with its SEC registered Alternative Trading System known as OTC Link(R) ATS. This system is owned by OTC Link(R), a subsidiary company of OTC Markets Group, that is a fully registered broker-dealer and member of FINRA. The OTCQX(R), OTCQB(R) and OTC Pink(R) platforms traded $135 billion of transactions in 2012 with an average daily dollar volume of $600 million, comprising 10,000 corporate securities; which includes 650 U.S. banks, 2,300 companies that report to the Securities and Exchange Commission (SEC), 1,600 companies that pay dividends, 1,400 American Depository Receipts (ADRs) and 1,400 foreign companies. Together these corporations boast an aggregate market capitalization of approximately $11.6 trillion.
Roger Dumoulin-White, President and CEO of Theralase stated that, "As Theralase continues to execute on its strategic initiatives and accelerate our growth in both our therapeutic and anti-cancer divisions, there is a growing interest south of the border to invest in our common stock. By changing venues from Grey Market to OTC Link(R), the Company is able to provide further transparency and financial reporting to our US based investors allowing them access to more information and hence a greater comfort in investing in Theralase. As Theralase delivers on its corporate milestones in both divisions in 2014 and 2015, it would be reasonable to expect the interest in acquiring Theralase common stock to increase among US based investors, leading Theralase to pursue full financial reporting and disclosure to the SEC to allow an eventual listing on a major US exchange, such as NASDAQ."
About Theralase Technologies Inc.
Theralase Technologies Inc. ("Theralase") (TSXV: TLT) (TLTFF: OTC Link(R)) designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration in numerous nerve, muscle and joint conditions. Theralase is developing patented Photo Dynamic Compound (PDC) technology that is able to target and destroy cancers, bacteria and viruses when light activated.
Additional information is available at www.theralase.com and www.sedar.com
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO, Theralase Technologies Inc.
1.866.THE.LASE (843.5273) x 225
416.699.LASE (5273) x 225
SOURCE: Theralase Technologies Inc.